 |
Video: What is a Stock Split?
|
 |
Diffusion Pharmaceuticals is a clinical stage biotechnology company. Co. is developing its primary product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC). TSC is designed to selectively target and re-oxygenate the micro-environment of hypoxic cells, and can potentially be used in various indications, including stroke, oncology and cardiovascular disease. Co.'s oncology program targets TSC against treatment-resistant brain cancer. In addition to the TSC programs, Co. is exploring alternatives to capitalize upon its product candidate RES-529, a PI3K/Akt/mTOR pathway inhibitor for age-related macular degeneration. According to our DFFN split history records, Diffusion Pharmaceuticals has had 3 splits. | |
 |

Diffusion Pharmaceuticals (DFFN) has 3 splits in our DFFN split history database. The first split for DFFN took place on August 19, 2016. This was a 1 for 10 reverse split, meaning for each 10 shares of DFFN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split. DFFN's second split took place on December 14, 2018. This was a 1 for 15 reverse split, meaning for each 15 shares of DFFN owned pre-split, the shareholder now owned 1 share. For example, a 100 share position pre-split, became a 6.66666666666667 share position following the split. DFFN's third split took place on April 19, 2022. This was a 1 for 50 reverse split, meaning for each 50 shares of DFFN owned pre-split, the shareholder now owned 1 share. For example, a 6.66666666666667 share position pre-split, became a 0.133333333333333 share position following the split.
When a company such as Diffusion Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the DFFN split history from start to finish, an original position size of 1000 shares would have turned into 0.133333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Diffusion Pharmaceuticals shares, starting with a $10,000 purchase of DFFN, presented on a split-history-adjusted basis factoring in the complete DFFN split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/27/2013 |
|
End date: |
03/24/2023 |
|
Start price/share: |
$1,125.00 |
|
End price/share: |
$5.62 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.50% |
|
Average Annual Total Return: |
-41.14% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$49.98 |
|
Years: |
10.00 |
|
|
 |
Date |
Ratio |
08/19/2016 | 1 for 10 | 12/14/2018 | 1 for 15 | 04/19/2022 | 1 for 50 |
|
 |